Holen Sie sich die Stockscreener-App
70.02
7.59%
4.94
Handel nachbörslich:
69.67
-0.35
-0.50%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$65.08
Offen:
$64.445
24-Stunden-Volumen:
11.02M
Relative Volume:
1.99
Marktkapitalisierung:
$27.31B
Einnahmen:
$4.52B
Nettoeinkommen (Verlust:
$720.70M
KGV:
38.97
EPS:
1.7968
Netto-Cashflow:
$1.06B
1W Leistung:
+0.07%
1M Leistung:
-0.33%
6M Leistung:
-12.43%
1J Leistung:
-16.73%
1-Tages-Spanne:
$62.86
$71.34
1-Wochen-Bereich:
$62.86
$71.34
52-Wochen-Spanne:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
70.02 | 25.38B | 4.52B | 720.70M | 1.06B | 1.7968 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DexCom’s AI Stelo Upgrade Faces Valuation Questions After Share Declines - Sahm
DexCom Expands G7 And Stelo To Deepen CGM Ecosystem Engagement - Yahoo Finance UK
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom (DXCM) Maintains Buy Rating Despite Lowered Price Target - GuruFocus
Key facts: DexCom reports $2.8B profit; Wells Fargo cuts price target - TradingView
Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday? - Benzinga
Why Is DexCom (DXCM) Stock Rocketing Higher Today - Finviz
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth - TradingView
Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations - Yahoo Finance
Dexcom seeks expanded Medicare coverage of CGMs for Type 2 diabetes - MedTech Dive
Barclays Updates Rating on DexCom (DXCM) with Slight Price Targe - GuruFocus
DexCom (NASDAQ:DXCM) Stock Price Up 8.4% on Earnings Beat - MarketBeat
Wells Fargo & Company Has Lowered Expectations for DexCom (NASDAQ:DXCM) Stock Price - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Q4 2025 Earnings Call Transcript - Insider Monkey
DexCom (NASDAQ:DXCM) Price Target Raised to $90.00 - MarketBeat
Mizuho Securities Adjusts DexCom Price Target to $90 From $78, Maintains Outperform Rating - marketscreener.com
Wells Fargo Adjusts DexCom Price Target to $85 From $93, Maintains Overweight Rating - marketscreener.com
7 Analysts Have This To Say About DexCom - Benzinga
DexCom (DXCM) Gets a Reaffirmed "Buy" Rating from BTIG | DXCM St - GuruFocus
DexCom (NASDAQ:DXCM) Exceeds Q4 CY2025 Expectations - The Globe and Mail
Stifel reiterates Buy rating on DexCom stock, maintains $85 price target By Investing.com - Investing.com India
Stifel reiterates Buy rating on DexCom stock, maintains $85 price target - Investing.com
Decoding DexCom Inc (DXCM): A Strategic SWOT Insight - GuruFocus
DexCom Inc (DXCM) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Dexcom Q4 2025 presentation slides: double-digit growth amid margin expansion - Investing.com South Africa
DexCom Q4 2025 Earnings Call Insights - Intellectia AI
Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results - BioSpace
DexCom (DXCM) Surpasses Q4 2025 Earnings Expectations - GuruFocus
DexCom (NASDAQ:DXCM) Announces Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Dexcom (DXCM) Reports Strong Q4 Revenue with Promising Future Ou - GuruFocus
DexCom Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Dexcom Q4 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Dexcom Inc (NASDAQ:DXCM) Beats Q4 Profit Estimates Despite Revenue Shortfall - ChartMill
DexCom Reports Better-Than-Expected Q4 Results: Details - Bitget
Earnings call transcript: Dexcom Q4 2025 beats forecasts, stock dips - Investing.com
DEXCOM INC SEC 10-K Report - TradingView
DexCom (DXCM) Q4 Earnings and Revenues Top Estimates - Yahoo Finance Australia
Dexcom beats Street in Q4 on 13% sales growth - MassDevice
DexCom Q4 Adjusted Earnings, Revenue Rise; 2026 Outlook Reiterated - marketscreener.com
DexCom (DXCM) Q4 2025 Earnings Call Transcript - The Globe and Mail
DexCom: Q4 Earnings Snapshot - WKYC
Earnings Flash (DXCM) DexCom, Inc. Posts Q4 Adjusted EPS $0.68 per Share, vs. FactSet Est of $0.65 - marketscreener.com
DexCom Inc. Bottom Line Rises In Q4 - Nasdaq
Dexcom Stock in Focus: Can the Glucose Sensor Pioneer Regain Its Former Highs? - AD HOC NEWS
Investment Review: Is RMSG part of any major index2025 Big Picture & Real-Time Buy Signal Alerts - baoquankhu1.vn
DexCom earnings up next: Can G7 rollout offset Abbott competition? By Investing.com - Investing.com Canada
DexCom, Inc. (NASDAQ:DXCM) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
DexCom Stelo AI Upgrade Aims To Deepen Consumer Metabolic Health Engagement - Yahoo Finance
Dexcom Q4 2025 earnings preview - MSN
Earnings Preview: DexCom - Benzinga
What Are Wall Street Analysts' Target Price for DexCom Stock? - Yahoo Finance
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):